STEMI Management: Primary PCI, Fibrinolysis, DAPT Selection, and Door-to-Balloon Quality Metrics

Cardiology · Acute Coronary Syndrome

STEMI Management: Primary PCI, Fibrinolysis, DAPT Selection, and Door-to-Balloon Quality Metrics

Evidence-based STEMI care from prehospital ECG and triage through primary PCI, antithrombotic selection, complete revascularization, mechanical complication recognition, and post-MI guideline-directed medical therapy - aligned with 2023 ESC and 2025 ACC/AHA STEMI guidelines.

📅 Updated 2026-07-28 👨‍⚕️ gomdori, MD ⏱️ ~17 min read 📚 Evidence-graded

Executive Summary

STEMI represents complete thrombotic occlusion of an epicardial coronary artery requiring emergent reperfusion. Time is myocardium - every 30-minute delay in reperfusion increases 1-year mortality by approximately 7.5%. Primary PCI within 90 minutes door-to-balloon at PCI-capable centers (or 120 minutes FMC-to-device at non-PCI centers requiring transfer) is the dominant strategy. Fibrinolysis remains essential when timely PCI is unavailable - administered within 30 minutes door-to-needle followed by routine angiography 3-24 hours later (pharmaco-invasive strategy). Antithrombotic regimen: aspirin 325 mg load + ticagrelor 180 mg load (or prasugrel 60 mg if low-bleeding-risk PCI candidate, or clopidogrel 600 mg if fibrinolysis or contraindications) + heparin or bivalirudin during PCI. Radial access reduces bleeding and mortality (MATRIX, RIVAL trials) - now Class I. Complete revascularization of significant non-culprit lesions during index admission or staged within 4-6 weeks improves outcomes (COMPLETE, FULL REVASC) - except in cardiogenic shock (CULPRIT-SHOCK). Post-MI GDMT pillars include 12-month DAPT, high-intensity statin (LDL <55), beta-blocker, ACEi/ARB (mandatory if EF <40%), aldosterone antagonist (EF <40% with HF/DM), SGLT2 inhibitor, and cardiac rehab.

90 minDoor-to-balloon target
30 minDoor-to-needle (fibrinolysis)
12 moStandard DAPT duration
<55LDL target (mg/dL) post-MI

1. Pathophysiology and ECG Diagnosis

Atherothrombosis: The Vulnerable Plaque Cascade

STEMI results from acute thrombotic occlusion of an epicardial coronary artery. The proximate event is plaque rupture (60-70% of cases) or plaque erosion (30-40%) of a previously non-flow-limiting atheroma. The vulnerable plaque is characterized by a thin fibrous cap (less than 65 micrometers), large lipid-rich necrotic core, infiltration by activated macrophages and T cells, and surface inflammation. Triggers include adrenergic surges (morning, exercise, emotional stress), inflammation (sepsis, surgery), and prothrombotic states.

Plaque rupture exposes subendothelial collagen and tissue factor, triggering platelet adhesion via GPIb-vWF and GPVI-collagen, platelet activation through thromboxane A2 and ADP release, GPIIb/IIIa-mediated platelet aggregation, and tissue factor-driven thrombin generation. The resulting platelet-fibrin thrombus completely occludes the vessel, producing transmural ischemia. Without reperfusion, irreversible myocyte necrosis begins within 20-30 minutes (subendocardial wavefront) and progresses outward over 6 hours, after which most salvageable myocardium is lost.

Reperfusion within 90-120 minutes salvages substantial myocardium. Beyond 12 hours, mechanical reperfusion offers diminishing benefit unless symptoms persist or hemodynamic instability is present. The "open artery hypothesis" - late reperfusion offers structural and electrical benefit beyond myocardial salvage - has been largely refuted (OAT trial). Right ventricular infarction (40% of inferior STEMI) involves the proximal RCA before the RV branch and is recognized by V4R ST elevation - treated with volume loading, avoidance of nitrates/diuretics, and emergent reperfusion.

STEMI ECG Diagnostic Criteria

Standard criteria (4th Universal Definition of MI, 2018):

  • New ST elevation at the J-point in 2 contiguous leads
  • ≥1 mm in all leads except V2-V3
  • V2-V3 thresholds: ≥2 mm men age ≥40, ≥2.5 mm men <40, ≥1.5 mm women regardless of age
  • Reciprocal ST depression in opposing leads supports the diagnosis
Lead DistributionCoronary TerritoryReciprocal ChangesClinical Notes
V1-V4 (anterior)LAD - proximal or midII, III, aVFLargest infarct; high mortality; LV failure risk
V1-V6 + I, aVL (extensive anterior)Proximal LAD before D1II, III, aVFAnterior + lateral; very high mortality; cardiogenic shock
I, aVL, V5-V6 (lateral)LCx or D1 of LADII, III, aVFOften missed; check posterior leads
II, III, aVF (inferior)RCA (80%) or LCx (20%)I, aVLCheck V4R for RV infarct; hypotension with nitrates
V4R ST elevation ≥1 mm (RV infarct)Proximal RCA—Volume loading; avoid nitrates/diuretics
ST depression V1-V3 with tall R (posterior)LCx or RCA (PDA)V7-V9 ST elevation ≥0.5 mmOften missed - obtain posterior leads
Sinus tachycardia + diffuse ST↑ + aVR ST elevationLeft main coronary arteryDiffuse ST depressionCardiogenic shock; emergent PCI

STEMI Equivalents (Treat as STEMI)

  • New LBBB with Sgarbossa criteria: concordant ST elevation ≥1 mm (5 points), concordant ST depression ≥1 mm V1-V3 (3 points), discordant ST elevation ≥5 mm or Smith modification (excessive discordance ratio >0.25) - score ≥3 highly specific for acute MI.
  • Posterior STEMI: ST depression ≥0.5 mm in V1-V3 with prominent R waves; confirm with posterior leads V7-V9 (≥0.5 mm ST elevation diagnostic).
  • De Winter T waves: upsloping ST depression with tall symmetric T waves V1-V6 - proximal LAD occlusion equivalent.
  • aVR ST elevation ≥1 mm with diffuse ST depression: left main or proximal LAD occlusion.
  • Hyperacute T waves: tall, broad-based, asymmetric T waves - earliest STEMI sign, may precede ST elevation.
  • Wellens syndrome: deep T-wave inversions or biphasic T waves V2-V3 in pain-free state - critical proximal LAD stenosis, high MI risk.

⚠️ Always obtain serial 15-lead ECGs in suspected ACS

Initial ECG misses 30-40% of STEMI on first capture. Repeat at 10-15 minutes if symptoms persist. Add V7-V9 (posterior) and V3R-V4R (right-sided) leads for inferior or undifferentiated chest pain. Activate the cath lab on first diagnostic ECG - do not wait for troponin.

2. Risk Stratification and Initial Assessment

TIMI Risk Score for STEMI

The TIMI Risk Score for STEMI (8 variables, max 14 points) predicts 30-day mortality:

  • Age 65-74: 2 points; Age ≥75: 3 points
  • Diabetes, HTN, or angina history: 1 point
  • SBP <100 mmHg: 3 points
  • HR >100 bpm: 2 points
  • Killip class II-IV: 2 points
  • Weight <67 kg: 1 point
  • Anterior STEMI or LBBB: 1 point
  • Time to treatment >4 hours: 1 point

Mortality stratification: 0 points = 0.8%, 5 points = 12%, 8+ points = 36% at 30 days. High TIMI score (≥5) flags need for ICU admission, mechanical support readiness, and aggressive revascularization.

Killip Classification (Hemodynamic Status)

ClassClinical Findings30-day MortalityImplication
INo HF signs~6%Standard care
IIS3 gallop, basal rales, JVD~17%Diuretics, ACEi early
IIIPulmonary edema~38%NIV/intubation, IV diuretics, vasodilators
IVCardiogenic shock (SBP <90, hypoperfusion)~80% (without MCS)Inotropes, MCS (Impella, IABP, VA-ECMO), urgent PCI of culprit only

Initial ED Management Bundle (First 30 Minutes)

  1. Recognize STEMI on prehospital or door ECG within 10 minutes of arrival.
  2. Activate cath lab immediately on diagnostic ECG (parallel processing - do not wait for labs).
  3. IV access × 2 (large-bore peripheral; femoral central if shock).
  4. Cardiac monitor and defibrillator at bedside - VF/pulseless VT highest in first hour.
  5. Oxygen only if SaO2 <90% (DETO2X-AMI: routine O2 not beneficial and possibly harmful).
  6. Aspirin 325 mg PO chewed immediately (or 162 mg).
  7. P2Y12 inhibitor: ticagrelor 180 mg PO load (preferred) OR prasugrel 60 mg (if PCI candidate, no contraindications) OR clopidogrel 600 mg.
  8. Anticoagulation: unfractionated heparin 60 U/kg IV bolus (max 4000 U) → 12 U/kg/hr infusion (max 1000 U/hr) targeting aPTT 50-70 seconds; OR enoxaparin 30 mg IV bolus + 1 mg/kg SC; OR bivalirudin 0.75 mg/kg IV bolus then 1.75 mg/kg/hr.
  9. Pain control: sublingual or IV nitroglycerin (avoid in inferior/RV MI, hypotension, recent PDE5 inhibitor); morphine 2-4 mg IV (use sparingly - delays oral antiplatelet absorption per IMPRESSION trial).
  10. Beta-blocker: oral metoprolol 25 mg if hemodynamically stable (avoid IV beta-blocker in shock per COMMIT trial).
  11. Statin: high-intensity (atorvastatin 80 mg or rosuvastatin 40 mg) on arrival.
  12. Notify family, prepare for transport to cath lab.

🚨 Avoid in STEMI

(1) NSAIDs other than aspirin - increase mortality, reinfarction, hypertension. (2) Routine high-flow oxygen if SaO2 ≥90% - increases coronary vasoconstriction. (3) IV beta-blockers in unstable hemodynamics or signs of HF (Killip ≥III) - associated with cardiogenic shock per COMMIT. (4) Nitrates in inferior STEMI with RV involvement - profound hypotension. (5) Routine GPIIb/IIIa inhibitors with bivalirudin - adds bleeding without ischemic benefit. (6) Empiric thrombolysis without confirmed STEMI ECG.

3. Primary PCI vs Fibrinolysis Decision

Reperfusion Timing Algorithm

STEMI reperfusion decision tree based on PCI availability and timing Algorithm: STEMI diagnosis to primary PCI within 90/120 min vs fibrinolysis within 30 min STEMI Reperfusion Decision Algorithm STEMI Diagnosis PCI capable? YES, ≤120min FMC NO or >120min PRIMARY PCI D2B ≤90 min FMC2D ≤120 min Class I, LOE A FIBRINOLYSIS D2N ≤30 min Then transfer for PCI 3-24h Pharmaco-invasive Cardiogenic shock or fibrinolysis contraindication: PCI mandatory regardless of timing
Reperfusion decision: PCI ≤120 min FMC = primary PCI; otherwise fibrinolysis within 30 min then transfer for routine 3-24h PCI.

Fibrinolytic Selection and Dosing

AgentDoseNotes
Tenecteplase (TNK-tPA)Single IV bolus 30-50 mg (weight-based: <60 kg = 30 mg, 60-69 = 35, 70-79 = 40, 80-89 = 45, ≥90 = 50; HALF-DOSE if age ≥75)Most fibrin-specific; preferred in modern practice; STREAM half-dose elderly trial
Alteplase (rt-PA)15 mg IV bolus → 0.75 mg/kg over 30 min (max 50) → 0.5 mg/kg over 60 min (max 35); total ≤100 mgOriginal lytic; complex dosing
Reteplase (r-PA)10 U IV bolus, repeat at 30 minLess fibrin-specific than TNK
Streptokinase (rare)1.5 million U IV over 30-60 minAntigenic, lower efficacy; mostly historical or LMIC use

Adjunctive antithrombotics with fibrinolysis:

  • Aspirin 325 mg load → 81 mg daily lifelong
  • Clopidogrel 300 mg load (75 mg if age >75 due to bleeding risk) → 75 mg daily for 14 days minimum, then per stent
  • Enoxaparin: 30 mg IV bolus + 1 mg/kg SC q12h (no IV bolus and 0.75 mg/kg q12h if age ≥75; 1 mg/kg q24h if CrCl <30); duration up to hospital discharge or 8 days
  • Alternative: UFH 60 U/kg IV bolus (max 4000) + 12 U/kg/hr infusion targeting aPTT 50-70 seconds for 48 hours

Absolute and Relative Contraindications to Fibrinolysis

AbsoluteRelative
  • Prior intracranial hemorrhage (any time)
  • Known structural cerebral vascular lesion (AVM)
  • Known malignant intracranial neoplasm
  • Ischemic stroke within 3 months (except acute, <4.5 hours)
  • Suspected aortic dissection
  • Active bleeding or bleeding diathesis
  • Significant closed head or facial trauma within 3 months
  • Intracranial or intraspinal surgery within 2 months
  • Severe uncontrolled hypertension (SBP >200, DBP >120) not responsive to therapy
  • History of chronic, severe, poorly controlled HTN
  • SBP >180 or DBP >110 on presentation
  • History of ischemic stroke >3 months ago
  • Dementia or known intracranial pathology not covered above
  • Traumatic or prolonged (>10 min) CPR
  • Major surgery within 3 weeks
  • Recent (within 2-4 weeks) internal bleeding
  • Noncompressible vascular punctures
  • For streptokinase: prior exposure (within 5 days to 2 years) or allergy
  • Pregnancy
  • Active peptic ulcer
  • Current oral anticoagulant use (high INR raises risk)

Failed Fibrinolysis - Rescue PCI

Assess reperfusion at 60-90 minutes post-fibrinolysis. Indicators of failure: less than 50% ST resolution in the worst lead, persistent chest pain, hemodynamic or electrical instability. Rescue PCI improves outcomes (REACT trial) - emergent transfer for catheterization. Successful fibrinolysis still warrants routine angiography 3-24 hours later (CARESS-in-AMI, TRANSFER-AMI) - the pharmaco-invasive strategy.

STEMI Management — Procedure Steps Surgical stepper: STEMI Management — Procedure Steps STEMI Management — Procedure Steps 1 Initial ED management ASA 162-325mg chewed + ticagrelor 180mg loading + UFH 60 U/kg + activate cath lab; oxygen only if Sp 2 Primary PCI DES preferred over BMS; access radial > femoral; stent the culprit lesion; consider complete revascu 3 Fibrinolysis (if PCI delay) Tenecteplase IV bolus weight-based: <60kg = 30mg, 60-69 = 35mg, 70-79 = 40mg, 80-89 = 45mg, ≥90 = 50 4 Antithrombotic continuation DAPT × 12 mo (ASA 81mg + ticagrelor 90mg BID); UFH/enoxaparin during PCI; bivalirudin if HIT 5 Adjunctive therapy High-intensity statin (atorva 80mg or rosuva 40mg); BB if no contraindication; 6 Mechanical complications VSD, papillary muscle rupture, free wall rupture: immediate cardiac surgery; tamponade: pericardioce
STEMI Management — Procedure Steps

4. Antithrombotic Therapy and DAPT Selection

P2Y12 Inhibitor Comparison

DrugLoading / MaintenanceOnsetReversalTrialNotes
Ticagrelor (Brilinta)180 mg load → 90 mg BID30 minNone (12h half-life)PLATOPreferred 1st-line ESC 2023; reversible inhibition; dyspnea (15%); avoid with strong CYP3A4 inhibitors; lifelong aspirin 81 mg co-administered
Prasugrel (Effient)60 mg load → 10 mg daily (5 mg if <60 kg or age ≥75)30 minNoneTRITON-TIMI 38, ISAR-REACT 5Superior to ticagrelor for PCI (ISAR-REACT 5); contraindicated with prior stroke/TIA, age ≥75 unless DM/prior MI
Clopidogrel (Plavix)600 mg load → 75 mg daily (300 mg load if age >75 with fibrinolysis)2-6 hNoneCLARITY, COMMITUse if ticagrelor/prasugrel contraindicated; CYP2C19 *2/*3 reduced metabolism (genotyping per TAILOR-PCI); standard with fibrinolysis
Cangrelor30 mcg/kg IV bolus + 4 mcg/kg/min infusion2 min~60 minCHAMPION-PHOENIXIV reversible; useful when oral antiplatelet not feasible (intubated, vomiting); transition to oral within 30 min of stop

Anticoagulation During PCI

  • Unfractionated heparin: 70-100 U/kg IV bolus (50-70 U/kg if GPIIb/IIIa inhibitor planned), target ACT 250-300 sec (200-250 with GPIIb/IIIa). Most commonly used; reversible with protamine.
  • Bivalirudin: 0.75 mg/kg IV bolus + 1.75 mg/kg/hr infusion. Equivalent ischemic outcomes vs UFH with less bleeding (HORIZONS-AMI, MATRIX). Preferred for patients at high bleeding risk; expensive.
  • Enoxaparin: 0.5 mg/kg IV bolus during PCI for patients pretreated with SC enoxaparin (ATOLL trial supportive but not definitive).
  • Fondaparinux: NOT for primary PCI (catheter thrombus risk per OASIS-6) - only with conservative or fibrinolytic strategy.

GPIIb/IIIa Inhibitors

Routine upstream GPIIb/IIIa is no longer recommended (BRAVE-3, FINESSE). Reserved for "bailout" use during PCI for high thrombus burden, slow flow/no-reflow, or thrombotic complications. Agents: abciximab 0.25 mg/kg bolus + 0.125 mcg/kg/min × 12h; eptifibatide 180 mcg/kg bolus × 2 + 2 mcg/kg/min × 12h; tirofiban 25 mcg/kg over 3 min + 0.15 mcg/kg/min × 12h. Major bleeding ×2 vs placebo - balance against ischemic benefit case-by-case.

DAPT Duration and De-escalation Strategies

Standard: 12 months DAPT after drug-eluting stent for STEMI. Recent trials support flexibility:

  • High bleeding risk: abbreviated 1-3 months DAPT then aspirin or P2Y12 monotherapy (MASTER DAPT, STOPDAPT-2 ACS) - maintains ischemic protection with less bleeding.
  • Low bleeding risk + high ischemic risk: extend DAPT beyond 12 months or use ticagrelor 60 mg BID monotherapy (PEGASUS-TIMI 54) - 1-3 years of extended therapy reduces ischemic events.
  • De-escalation: switch from ticagrelor/prasugrel to clopidogrel after 1-3 months in patients with bleeding events or platelet function-guided strategy (TROPICAL-ACS).
  • Triple therapy with concomitant AF: 1 week DAPT + DOAC then DOAC + clopidogrel for 6-12 months then DOAC monotherapy (AUGUSTUS, ENTRUST-AF-PCI, RE-DUAL PCI) - minimizes bleeding while preserving ischemic protection.

💎 Pearl: ISAR-REACT 5 changed the prasugrel-vs-ticagrelor calculus

For PCI-treated ACS patients without prasugrel contraindications (no prior stroke/TIA, age <75, weight ≥60 kg), ISAR-REACT 5 (2019) showed prasugrel reduced the composite of death/MI/stroke vs ticagrelor (6.9% vs 9.3%, HR 0.83) without increased major bleeding. Prasugrel is now preferred in PCI candidates meeting criteria. Ticagrelor remains first-line when angiographic anatomy is unknown (medical management or pre-cath), prior stroke/TIA, or in fibrinolysis - and offers lifestyle simplicity (BID dosing).

⚠️ Pitfall: Mixing aspirin doses with ticagrelor

PLATO subgroup analysis showed reduced ticagrelor benefit with aspirin doses >100 mg/day (US site effect, possibly attributable to higher aspirin dosing). Always pair ticagrelor with aspirin 75-100 mg/day - NOT 325 mg/day for chronic maintenance. Loading dose aspirin 325 mg one-time is fine; maintenance must be low-dose. This is one of the most common prescribing errors in post-MI care.

5. PCI Strategy, Complete Revascularization, and Cardiogenic Shock

Radial vs Femoral Access

Radial access is now Class I (ESC 2023, ACC/AHA 2025). MATRIX (8404 ACS patients) and RIVAL (7021 ACS) showed radial access reduces major bleeding by 50% and mortality by 30% vs femoral in STEMI. Operator volume matters - centers and operators with lower radial volumes show attenuated benefit. Modern dual access strategies: radial primary, femoral backup for hemodynamic support (Impella, IABP, ECMO cannulation).

Stent Selection

  • Drug-eluting stents (DES) preferred over bare-metal stents for all STEMI - reduced restenosis with equivalent stent thrombosis rates in modern second-generation DES (everolimus, zotarolimus).
  • Bioresorbable scaffolds: initial enthusiasm tempered by ABSORB III long-term data showing increased late thrombosis - largely abandoned.
  • Drug-coated balloons (DCB): useful for in-stent restenosis, small vessels (≤2.5 mm), bifurcation side branches, and high bleeding risk - allows shorter DAPT.
  • Aspiration thrombectomy: NOT routine (TASTE, TOTAL trials neutral; possible stroke signal). Reserved for high thrombus burden when adjunct techniques (no-reflow management) needed.

Complete Revascularization Strategy

For multi-vessel disease in stable STEMI patients (50-60% of STEMI):

  • COMPLETE trial (2019): staged PCI of significant non-culprit lesions (within 45 days) reduced CV death/MI by 26% vs culprit-only.
  • FULL REVASC (2024): FFR-guided complete revascularization at index admission noninferior to staged.
  • FIRE (2023): in older adults (≥75) with multivessel STEMI, complete revascularization superior to culprit-only (15.7% vs 20.6% MACE at 1 year).
  • Strategy: Complete during index admission (preferred for stable patients) OR staged within 4-6 weeks. Use FFR/iFR or angiographic stenosis ≥70% to identify hemodynamically significant non-culprit lesions.

🚨 EXCEPTION: Cardiogenic shock - culprit-only PCI

CULPRIT-SHOCK trial (2017): in STEMI complicated by cardiogenic shock, culprit-only PCI at index procedure REDUCED 30-day mortality vs immediate multi-vessel PCI (45.9% vs 51.5%). Mechanism: contrast load, prolonged procedure time, and additional ischemic burden in already-stressed patient. Stage non-culprit revascularization after stabilization. This is the key STEMI guideline exception to remember.

Cardiogenic Shock Management

Defined as SBP <90 mmHg for ≥30 min (or vasopressors required to maintain SBP ≥90), with hypoperfusion (cool extremities, oliguria, altered mental status, lactate >2). Mortality 30-50% with current therapy.

Mechanical Circulatory Support Hierarchy

DeviceHemodynamic EffectIndicationTrial Evidence
IABPModest CO augmentation (0.5 L/min); afterload reductionBridge to recovery or definitive therapy; no longer Class I in shockIABP-SHOCK II (negative)
Impella CP/5.52.5-5.5 L/min unload of LV; direct ventricular unloadingPre-PCI insertion preferred; STEMI shock; high-risk PCIDanGer Shock (2024 - positive!)
VA-ECMOFull cardiopulmonary support; complete cardiac unloading possible with LV ventRefractory shock; biventricular failure; hypoxemicEURO-ECMO-SHOCK (mixed)
TandemHeartTrans-septal LA→femoral artery 4 L/minRV failure or severe biventricular shockLimited RCT data

DanGer Shock (2024): Impella CP plus standard care vs standard care alone in STEMI cardiogenic shock - 6-month mortality 45.8% vs 58.5% (HR 0.74). First positive trial of mechanical support in cardiogenic shock. Adopted into 2024 ESC heart failure focused update as a tool to consider in selected patients. Vascular complications (severe bleeding, limb ischemia, hemolysis) higher with Impella - careful patient selection required.

Vasoactive Strategy in Cardiogenic Shock

  • Norepinephrine first-line vasopressor (lower mortality vs epinephrine per OptimaCC trial)
  • Dobutamine 2.5-10 mcg/kg/min for inotropic support in normotensive patients with low CO
  • Milrinone 0.25-0.75 mcg/kg/min for inotropy without beta-receptor stimulation; useful in beta-blocker-treated patients but causes hypotension
  • Avoid epinephrine as primary vasopressor (more arrhythmia, lactic acidosis)

Practice Insights — Bedside Notes on STEMI Primary PCI

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Across published practice patterns, the two patterns experienced clinicians keep refining are recognizing "STEMI without ST elevation" patterns that deserve emergent cath despite the textbook ECG criteria being absent, and committing to pharmaco-invasive strategy when transfer for primary PCI cannot meet the 120-minute window.

The "STEMI Without ST Elevation" Patterns That Need Cath

Several ECG patterns are functionally equivalent to STEMI but do not meet the classical ST-elevation criteria, and seasoned clinicians treat all of them with emergent cath activation in practice. Posterior STEMI: tall R waves and ST depression in V1–V3 mirror the unseen posterior ST elevation; confirm with posterior leads V7–V9. De Winter T waves: upsloping ST depression with tall symmetric T waves in precordial leads = proximal LAD occlusion equivalent. Wellens syndrome: deeply inverted or biphasic T waves in V2–V3 in a pain-free patient — critical LAD lesion that will infarct without intervention. Isolated aVR ST elevation: left main or triple-vessel disease. Modified Sgarbossa criteria in LBBB: concordant ST elevation, concordant ST depression, or discordant ST elevation >1 mm with ST/S ratio. These get the same activation as a textbook STEMI.

FMC-to-Balloon Time Anchors the Decision

The first medical contact (FMC) to balloon time goal is ≤90 minutes at a PCI center and ≤120 minutes if transfer is required. In practice the FMC-to-balloon clock starts when EMS arrives or the patient registers in a non-PCI ED; the cath lab activation happens off the field ECG with EMS, not after re-confirmation at the ED. Pre-arrival aspirin 162–325 mg chewed, ticagrelor 180 mg loaded, and unfractionated heparin 60 U/kg IV bolus are given by EMS or the referring ED so the patient arrives at the table loaded. If projected FMC-to-balloon exceeds 120 minutes, pharmaco-invasive strategy is the answer, not heroic transport.

Pharmaco-Invasive Strategy When Transfer Delay >120 Min

For patients presenting to non-PCI centers where transfer for primary PCI will exceed 120 minutes from FMC, the pharmaco-invasive strategy beats prolonged transfer. Tenecteplase 30–50 mg IV single bolus (weight-adjusted) plus aspirin, clopidogrel 300 mg load (NOT ticagrelor or prasugrel with fibrinolysis), and enoxaparin 30 mg IV bolus + 1 mg/kg SC q12h. Transfer to a PCI center is initiated immediately after fibrinolytic administration, with cath performed at 2–24 hours regardless of clinical response. Rescue PCI immediately if no clinical reperfusion at 60–90 minutes post-fibrinolytic. The pharmaco-invasive approach gives most patients reperfusion within the window when geography prevents primary PCI.

Inferior STEMI With V4R Elevation = RV Infarct — No Nitrates

Inferior STEMI patients (ST elevation in II, III, aVF) need V4R checked routinely because right ventricular infarction in the setting of inferior STEMI is preload-dependent and acutely sensitive to nitroglycerin. RV STEMI clues: lead II ST elevation greater than lead III, V4R ST elevation greater than 1 mm, hypotension on small nitro dose. In practice inferior STEMI patients get a 12-lead with right-sided V4R added before any nitroglycerin is dosed. If RV infarction is present, IV fluids are first-line (250–500 mL boluses titrated to BP) and nitroglycerin is contraindicated. Experienced practitioners have personally watched outside hospitals give SL nitro to RV STEMI patients and induce profound hypotension that took 30 minutes of crystalloid plus norepinephrine to reverse.

Illustrative Scenario — Pre-Hospital Activation, Door-to-Balloon 45 Minutes

(Composite teaching scenario assembled from published patterns; not an individual patient.)

A man in his late 50s, smoker with hypertension, developed crushing substernal chest pain at home for 40 minutes before calling EMS. Pre-hospital 12-lead ECG transmitted to the receiving cath lab showed 4 mm ST elevation in V1–V4 with reciprocal depression in II, III, aVF — anterior STEMI from likely proximal LAD occlusion. The cath lab activation went out from EMS directly, bypassing the ED. EMS gave aspirin 325 mg chewed, ticagrelor 180 mg PO load, unfractionated heparin 60 U/kg IV bolus en route. The patient bypassed ED triage and went straight to the cath lab on arrival. First medical contact to balloon inflation time was 45 minutes; the culprit was a proximal LAD 100% thrombotic occlusion, treated with aspiration thrombectomy followed by drug-eluting stent. Door-to-balloon (registration to inflation) was 28 minutes; pre-discharge LVEF 45% with anterior wall hypokinesis. He was discharged on day 4 on aspirin 81, ticagrelor 90 BID, atorvastatin 80, carvedilol uptitrated, lisinopril 10, dapagliflozin 10, with cardiac rehab in week 1.

Takeaway: pre-hospital ECG transmission with EMS-direct cath lab activation is the highest-yield STEMI system intervention available. Door-to-balloon is the wrong metric; FMC-to-balloon is what saves myocardium.

Protocol Adjustments Experienced Clinicians Use Beyond the Standard Guideline

  • Pre-hospital ECG with EMS-direct cath lab activation — bypass ED triage when STEMI is clear on field ECG. Pre-arrival aspirin + ticagrelor + UFH so the patient arrives loaded for the table.
  • STEMI-equivalent ECG patterns activate emergent cath — posterior STEMI (V1–V3 mirror), de Winter T waves, Wellens, aVR elevation, modified Sgarbossa in LBBB. Don't wait for textbook ST elevation.
  • Pharmaco-invasive if projected FMC-to-balloon >120 min — TNK weight-adjusted single bolus + clopidogrel 300 mg load + enoxaparin. Transfer for PCI at 2–24 h regardless of clinical response.
  • Right-sided V4R lead on every inferior STEMI before any nitro — RV infarction is preload-dependent; nitroglycerin is contraindicated. IV fluids 250–500 mL boluses titrated to BP.
STEMI Pathway: FMC Clock + ECG Equivalents + Pharmaco-Invasive Fallback STEMI activation pathway showing pre-hospital ECG with FMC-to-balloon time clock, STEMI-equivalent ECG pattern grid for emergent activation, primary PCI vs pharmaco-invasive decision branch by transfer time, and right-sided V4R rule for inferior STEMI. STEMI: FMC-to-Balloon Is the Clock, Not Door-to-Balloon Pre-hospital ECG + EMS-direct activation saves myocardium STEP 1 — FMC-to-balloon clock starts at EMS arrival or non-PCI ED registration Pre-arrival ASA 325 + ticagrelor 180 + UFH 60 U/kg · bypass ED triage STEP 2 — STEMI-equivalent ECG patterns also activate emergent cath Posterior STEMI V1–V3 mirror image Confirm V7–V9 de Winter T / Wellens Proximal LAD equivalent Will infarct without PCI aVR elevation / Sgarbossa LBBB LMCA / 3VD / acute MI in LBBB Modified Sgarbossa criteria STEP 3 — Reperfusion strategy by projected FMC-to-balloon time ≤120 min projected → PRIMARY PCI Goal ≤90 min at PCI center · ≤120 min transfer Aspiration thrombectomy + DES >120 min → PHARMACO-INVASIVE TNK + clopi 300 + enoxaparin → transfer Cath at 2–24 h regardless of clinical response INFERIOR STEMI — Add V4R BEFORE any nitroglycerin II>III ST elevation + V4R >1 mm = RV infarction → preload-dependent Nitroglycerin CONTRAINDICATED · IV fluids 250–500 mL boluses titrated to BP

6. Mechanical Complications, Post-MI GDMT, and FAQ

Mechanical Complications (3-7 Days Post-MI)

Era of routine reperfusion has reduced incidence of mechanical complications from 5-10% to under 2%, but mortality remains high without prompt recognition.

ComplicationTimingClinical PictureDiagnosisManagement
Free wall ruptureDay 3-7Sudden hemodynamic collapse, PEA arrest, tamponadeBedside echo: pericardial effusion, tamponadeEmergent surgery; pericardiocentesis temporizing; mortality >90%
Ventricular septal defect (VSD)Day 3-5 (anterior MI - apical VSD; inferior MI - basal VSD)New harsh holosystolic murmur, biventricular failureEcho with color Doppler; RV oxygen step-up on PA cathIABP/Impella bridge; surgical closure (delayed if possible) or percutaneous device
Papillary muscle ruptureDay 3-5; usually inferior MI (posteromedial PM has single blood supply)Acute severe MR, flash pulmonary edema, hypotension, shockEcho: flail leaflet, severe MR jetEmergent valve repair/replacement; IABP bridge; mortality 50% even with surgery
LV pseudoaneurysmDays to weeksContained rupture - thrombus seals defectEcho: narrow neck, broad sacUrgent surgical repair (high rupture risk)
True LV aneurysmWeeks to monthsPersistent ST elevation; HF symptoms; ventricular arrhythmiaEcho or cardiac MRIAnticoagulation if thrombus; surgery for HF/arrhythmia refractory cases
LV thrombusDays to weeks (anterior MI, EF <30%)Often asymptomatic; embolic strokeEcho with contrast or cardiac MRI (MRI more sensitive)Warfarin 3-6 months (target INR 2-3); DOAC growing evidence
Dressler syndrome2-10 weeks post-MIPleuropericarditis, fever, pericardial effusionClinical + echo; ECG diffuse PR depressionNSAIDs (avoid in early post-MI), colchicine 0.6 mg BID × 3 months; corticosteroids if refractory
Post-infarction ventricular arrhythmiaHours to daysSustained VT/VFTelemetry, ECGBeta-blocker, amiodarone, ICD evaluation if EF ≤35% at 40 days post-MI per MADIT-II

Post-MI GDMT - Five Pillars

PillarDrug Class / ExamplesIndicationTarget
1. AntiplateletAspirin 81 mg + ticagrelor 90 mg BID (or prasugrel 10 mg, or clopidogrel 75 mg)All post-MIDAPT 12 months → aspirin lifelong
2. Lipid loweringHigh-intensity statin (atorvastatin 80 mg, rosuvastatin 20-40 mg); add ezetimibe 10 mg, PCSK9 inhibitor (alirocumab/evolocumab) if neededAll post-MILDL <55 mg/dL (≥50% reduction from baseline)
3. Beta-blockerMetoprolol succinate 25-200 mg, carvedilol 6.25-25 mg BID, bisoprolol 1.25-10 mgAll post-MI; especially EF <40% (CAPRICORN)HR 60-70 bpm; titrate to max tolerated
4. RAAS inhibitionACEi (lisinopril, ramipril, enalapril) or ARB (valsartan, candesartan); ARNI (sacubitril-valsartan) if EF reducedEF <40%, anterior MI, DM, HTN, CKDMax tolerated dose; check Cr/K+ at 1-2 weeks
5. Aldosterone antagonistEplerenone 25-50 mg or spironolactone 25 mgEF <40% with HF symptoms or DM (EPHESUS)K+ <5.0; eGFR >30
6. (NEW) SGLT2 inhibitorDapagliflozin 10 mg, empagliflozin 10 mgEF <40%, DM, CKD; emerging post-MI evidence (DAPA-MI, EMPACT-MI)Once daily regardless of glucose
7. Cardiac rehabilitationSupervised exercise + risk factor modification + educationAll post-MI36 sessions over 12 weeks

Quality Metrics and Performance Measures

  • Door-to-balloon (D2B): ≤90 minutes for primary PCI (≥75% of cases) - CMS quality measure
  • FMC-to-device: ≤120 minutes for transferred patients
  • Door-to-needle (D2N): ≤30 minutes for fibrinolysis
  • Aspirin within 24 hours: ≥98% of STEMI patients
  • Beta-blocker at discharge: ≥95% (excluding contraindications)
  • Statin at discharge: ≥95%
  • ACEi/ARB at discharge if EF ≤40%: ≥95%
  • Cardiac rehab referral: ≥85%

Discharge Checklist

📋 Pre-discharge bundle

Medications: aspirin 81 mg + P2Y12 + high-intensity statin + beta-blocker + ACEi/ARB if indicated + aldosterone antagonist if EF <40% with HF/DM + SGLT2i if indicated. Imaging: pre-discharge TTE for EF, regional wall motion, valvular complications, LV thrombus. Risk modification: smoking cessation counseling + pharmacotherapy (varenicline, NRT), influenza/pneumococcal vaccination, glycemic control, BP <130/80, weight management. Activity: cardiac rehab referral; gradual return to activity; sexual activity safe at 1 week if asymptomatic. Follow-up: cardiology at 2 weeks (clinical assessment, lipid recheck at 4-6 weeks, ECG), primary care, EF reassessment at 40 days for ICD eligibility (if EF ≤35%).

When to Refer to Advanced Heart Failure

  • Refractory cardiogenic shock requiring durable MCS or transplant evaluation
  • Persistent EF ≤35% despite 3 months of GDMT - ICD ± CRT-D candidacy
  • Recurrent decompensated HF hospitalizations
  • Refractory ventricular arrhythmias
  • Mechanical complications requiring complex surgical repair

Frequently Asked Questions

What ECG criteria establish STEMI diagnosis?
New ST elevation at the J-point in 2 contiguous leads: ≥1 mm in all leads except V2-V3, where the threshold is ≥2 mm in men ≥40 years, ≥2.5 mm in men <40 years, and ≥1.5 mm in women regardless of age. New left bundle branch block (LBBB) with Sgarbossa criteria (concordant ST elevation ≥1 mm, concordant ST depression ≥1 mm in V1-V3, discordant ST elevation ≥5 mm) is treated as STEMI equivalent. Posterior STEMI (ST depression in V1-V3 with tall R waves) requires posterior leads V7-V9 (≥0.5 mm ST elevation diagnostic). Recognize hyperacute T waves and de Winter T-wave pattern as STEMI equivalents.
Primary PCI or fibrinolysis - how do I decide?
Primary PCI is preferred when first medical contact (FMC) to device time is ≤120 minutes. If transfer to a PCI-capable center exceeds 120 minutes from FMC, administer fibrinolysis within 30 minutes of arrival (door-to-needle ≤30 min) and transfer for routine angiography 3-24 hours post-fibrinolysis. PCI is mandatory regardless of timing for cardiogenic shock, contraindications to fibrinolysis, late presentation (>3 hours), or symptoms with ongoing ischemia. Door-to-balloon ≤90 minutes is the AHA/ACC quality metric for PCI-capable centers.
Which P2Y12 inhibitor should I use with aspirin?
Ticagrelor 180 mg loading then 90 mg BID is preferred first-line for STEMI per ESC 2023 (PLATO trial superiority over clopidogrel). Prasugrel 60 mg loading then 10 mg daily is preferred over ticagrelor in patients undergoing PCI without prior stroke/TIA, age <75, weight ≥60 kg (TRITON-TIMI 38, ISAR-REACT 5). Clopidogrel 600 mg load then 75 mg daily is reserved for fibrinolysis-treated patients (300 mg load if age >75) or when ticagrelor/prasugrel contraindicated. Continue DAPT 12 months after drug-eluting stent unless high bleeding risk warrants 1-3 month abbreviation per recent trials (MASTER DAPT, STOPDAPT-2).
Should I revascularize non-culprit lesions in multi-vessel STEMI?
Yes, complete revascularization is now Class I in stable STEMI patients with multivessel disease per COMPLETE (2019) and FULL REVASC (2024) trials - reduces MI and ischemia-driven revascularization. Strategy options: (1) PCI of non-culprit lesions during index admission (preferred), or (2) staged PCI within 4-6 weeks. EXCEPTION: in cardiogenic shock complicating STEMI, treat only the culprit lesion at index PCI per CULPRIT-SHOCK trial - non-culprit PCI worsened 30-day mortality. Use FFR/iFR or angiographic stenosis ≥70% to guide non-culprit lesion selection.
What is the post-MI GDMT regimen?
Five evidence-based pillars: (1) DAPT (aspirin 81 mg + ticagrelor/prasugrel/clopidogrel) 12 months then aspirin lifelong; (2) High-intensity statin (atorvastatin 80 mg or rosuvastatin 20-40 mg) targeting LDL <55 mg/dL; (3) Beta-blocker (metoprolol succinate 25-200 mg, carvedilol 6.25-25 mg BID) - especially with EF <40% (CAPRICORN); (4) ACE inhibitor or ARB (lisinopril, valsartan) - mandatory if EF <40%, anterior MI, diabetes, HTN, CKD; (5) Aldosterone antagonist (eplerenone 25-50 mg, spironolactone) if EF <40% with HF symptoms or diabetes (EPHESUS). Add SGLT2 inhibitor (dapagliflozin/empagliflozin 10 mg) and consider sacubitril-valsartan if EF reduced (PARADISE-MI/PIONEER-HF). Cardiac rehab Class I.
How do I recognize and manage mechanical complications?
Most mechanical complications occur 3-7 days post-MI. Free wall rupture (1-3%, fatal): sudden hemodynamic collapse, PEA arrest - emergent surgery, often unsuccessful. VSD (1-2%): new harsh holosystolic murmur, biventricular failure, RV oxygen step-up - mechanical support (IABP, Impella) bridge to surgical or percutaneous closure. Papillary muscle rupture (1%): acute severe mitral regurgitation, flash pulmonary edema, hypotension - emergent valve surgery. LV pseudoaneurysm: contained rupture - urgent surgery. Tamponade: Beck triad, pulsus paradoxus - urgent pericardiocentesis. Late complications: LV thrombus (anterior MI, EF <30% - anticoagulate 3-6 months), Dressler syndrome (pleuropericarditis 2-10 weeks post-MI - NSAIDs, colchicine).
↑

Leave a Reply

Your email address will not be published. Required fields are marked *